Pharmacy Times

JUNE 30, 2025

Accurate product labeling and ongoing safety monitoring remain essential for patient safety in CAR T therapies. Still, providing accurate product labeling for these products—which properly conveys the risks of CRS and neurological toxicities—remains essential to ensuring patient safety. Last Updated November 11, 2024.

Pharmacy Technician

Pharmacy Times

JULY 10, 2025

If approved, lumatperone’s expanded label could offer health care teams a valuable tool to improve stability, well-being, and real-world outcomes for patients with schizophrenia. 1-3 REFERENCES 1. Johnson & Johnson.

Pharmacy Technician

Pharmacy Times

JULY 15, 2025

December 3, 2024. months progression-free survival in real-world RRMM patients, consistent with KarMMa trial results. July 10, 2025. Doi:10.1182/blood.2024026216 2024026216 3. Study shows comparable safety, efficacy of idecabtagene vicleucel in older patients. Pharmacy Times. Accessed July 15, 2025. July 10, 2025. Doi:10.1182/blood.2025029274

Pharmacy Technician

Pharmacy Times

AUGUST 12, 2025

Image Credit: catalin | stock.adobe.com STARGLO Trial Overview Study Design and Population STARGLO was a global, randomized, open-label, phase 3 trial enrolling 274 patients across 62 centers in 13 countries. 011), respectively, with a cutoff date of June 17, 2024. 011), respectively, with a cutoff date of June 17, 2024.

Pharmacy Technician

Pharmacy Times

AUGUST 7, 2025

August 30, 2024. Antimicrobial Stewardship & Healthcare Epidemiology. 2025;5(1):e150. doi:10.1017/ash.2025.10048 2025.10048 2. RSV in Adults. News release. Updated July 8, 2025. Accessed August 7, 2025. RSV Vaccines. News release. Accessed April 17, 2025.

Long-Term Care Facilities

Pharmacy Times

JULY 22, 2025

This change mirrored a January 2025 FDA safety alert and label update that urged providers to consider genetic testing, inform patients of the risks, and discuss available options. billion in July 2024. Four others have been acquired, including Tobira Therapeutics, acquired by Allergan for up to $1.7

Pharmacy Technician

Pharmacy Times

JUNE 20, 2025

There are too many drug approvals, label updates, and new data published for even the most skilled and experienced oncology pharmacist to keep up with, let alone those still building their baseline knowledge. August 8, 2024. Updated January 19, 2024. LinkedIn Workplace Learning Report 2024. American Oncology Network.

Pharmacy Technician

Pharmacy Times

JULY 2, 2025

2,4 The open-label, single-arm, multicenter, multidose study enrolled 86 patients with CKD and hyperphosphatemia receiving maintenance hemodialysis. November 11, 2024. The trial’s primary objective was to evaluate the tolerability of OLC at its clinically effective doses (goal: serum phosphate ≤ 5.5 News release.

Pharmacy Technician

Pharmacy Times

JUNE 5, 2025

Detect-A-Dose lid-label cover enhances medication recognition, reducing packaging errors through a contrasting visual pattern. 1-3 Detect-A-Dose Lid Label Covers. 4 Detect-A-Dose features a contrasting black and white pattern on the underside of its label to make missing doses for patients apparent to pharmacists.

Pharmacy Technician

Pharmacy Times

JULY 18, 2025

The sBLA for glofitamab in combination with GemOx in R/R DLBCL was accepted by the FDA in December 2024. December 4, 2024. The dual targeting brings the T cell in close proximity to the B cell and then activates the release of proteins from the T cell that kill cancer cells. News release. Accessed July 18, 2025.

Pharmacy Technician

Pharmacy Times

JUNE 11, 2025

Its efficacy was evaluated in the 2 multicenter, single-arm open-label phase 2 clinical trials TRUST-I (NCT04395677) 3 and TRUST-II (NCT04919811). In TRUST-II, treatment with taletrectinib achieved a cORR of 62%, and as of October 2024 (the time of data cut-off), the median DOR was 19.4 Updated November 21, 2024.

Pharmacy Technician

Pharmacy Times

JUNE 12, 2025

Updated November 4, 2024. Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: A single-arm, open-label, phase 3 trial (ENVISION). 4 REFERENCES 1. A phase 3 single-arm study of UGN-102 for treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (ENVISION).

Pharmacy Technician

Pharmacy Times

JULY 9, 2025

The FDA has approved an updated label with a new recommended titration dosing schedule for donanemab-azbt (Kisunla; Eli Lilly and Company) for once-monthly amyloid-targeting therapy for adults that experience early symptomatic Alzheimer disease (AD). million individuals in the United States aged 65 and older.

Labelling

Pharmacy Times

JUNE 9, 2025

3 neoCARHP was a multicenter, open-label, randomized, noninferiority phase 3 trial (NCT04858529) that compared the efficacy and safety of TCbHP with THP in the neoadjuvant setting. If caught early, the cancer can often be treated and cured, according to Cleveland Clinic. Gao HF, Li W, Wu Z, et al. J Clin Oncol. doi:10.1200/JCO.2025.43.17_suppl.LBA500

Pharmacy Technician

Pharmacy Times

JUNE 20, 2025

In general, choosing a product that has broad spectrum on the label, covering both UV-A and UV-B rays and containing 20% zinc oxide, for her children will be optimal, especially for more sensitive areas of the skin. Updated August 9, 2024. August 28, 2024. August 28, 2024. June 21, 2024. Accessed May 12, 2025.

Pharmacy Technician

Pharmacy Times

AUGUST 7, 2025

TAI-SHAN5 is a phase 1, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, and anti-tumor efficacy of DZD8586 in patients with B-NHL. Updated July 23, 2024. Updated August 20, 2024. 1 Birelentinib has demonstrated favorable clinical benefit across multiple clinical trials.

HIV Treatment and Prevention Agents

PharmaTech

JUNE 25, 2025

EDQM has been promoting the use of alternative tests and removed the RPT in June 2024 from Ph. In July 2024, the United States Pharmacopeia (USP) announced it was permitting the use of non-animal-derived reagents for endotoxin testing (3).Susan July 26, 2024. Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs Paul L.

Dosage

Pharmaceutical Commerce

JULY 16, 2025

1 In response to this immense demand, coupled with high costs and accessibility issues, compounded alternatives have emerged as a seemingly pragmatic solution. However, these compounded GLP-1s are creating a significant, often underestimated, legal, reputational, and financial minefield for startups and the broader life sciences industry.

Compounding

Pharmacy Times

AUGUST 6, 2025

The CARTITUDE-1 trial reported a 98% overall response rate and significant progression-free survival, but experts urge caution in labeling cilta-cel as a cure. 1 Image Credit: LASZLO | stock.adobe.com However, despite these promising data, experts are cautious about labeling the therapy a cure. Updated April 2, 2024.

Pharmacy Technician

PharmaTech

JUNE 26, 2025

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines Feliza Mirasol April 30th 2024 Podcast In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Dosage

PharmaTech

JULY 17, 2025

3d render, number six glowing in the dark, pink blue neon light | Image Credit: © NeoLeo - stock.adobe.com Pharmaceutical compounding, particularly in 503A and 503B environments, involves complex formulation and regulatory challenges far beyond academic theory. antineoplastics, allergens). Check out the full article here !

Compounding

Pharmacy Times

JUNE 12, 2025

Molecular model of pembrolizumab | Image Credit: © Dr_Microbe - stock.adobe.com The FDA’s decision was based on data from the randomized, multicenter, open-label KEYNOTE-689 trial (NCT02358031). Updated September 20, 2024. This marks the first FDA approval for a perioperative treatment approach in locally advanced HNSCC.

Pharmacy Technician

Pharmaceutical Technology

JUNE 30, 2025

The planned 160,000ft² facility will focus on aseptic production and includes areas for material preparation and compounding. How will RFK Jr’s American dream for vaccines play out? Find out more Ground preparation work for the new site commenced in April after obtaining the building permit.

Packaging

Pharmacy Times

JUNE 15, 2025

In the randomized, open-label, multicenter phase 3 NATALEE clinical trial (NCT05306340), ribociclib (Kisqali; Novartis) plus endocrine therapy, a nonsteroidal aromatase inhibitor (NSAI), significantly improved invasive disease-free survival among individuals with HR-positive (HR+) and HER2-negative (HER2-) early breast cancer. March 20, 2024.

Pharmacy Technician

Pharmacy Times

JULY 1, 2025

1 To evaluate how temperature information is stored in the mouse brain, researchers designed a thermoregulatory Pavlovian conditioning experiment using engram labeling technology, which is a physical change in the brain that accounts for a specific memory. 1 The study included trained mice in context A at 21 °C and in context B at 4 °C.

Pharmacy Technician

Pharmacy Times

JUNE 23, 2025

In 2024, the FDA granted datopotamab a breakthrough therapy designation for patients with NSCLC based on data from the TROPION-Lung05 and TROPION-Lung01 trials that have since led to the agent’s accelerated approval. December 9, 2024. AstraZeneca. Accessed June 23, 2025. Pharmacy Times. June 19, 2025. Accessed June 23, 2025.

Pharmacy Technician

Pharmaceutical Technology

JULY 8, 2025

The pulmonary arterial hypertension (PAH) market is forecast to grow at a compound annual growth rate (CAGR) of 2.0% Symptoms such as fatigue, breathlessness, and chest pain are frequently misattributed to more common conditions, delaying intervention and compounding disease burden. Credit: Green Apple via Shutterstock.

Packaging

Pharmacy Times

JULY 21, 2025

It remains active in tumors that have developed resistance to first-, second-, and third-generation ALK inhibitors, including tumors with single or compound treatment-emergent ALK mutations. Updated December 13, 2024. September 14, 2024. ClinicalTrials.gov identifier: NCT05384626. Accessed July 21, 2025. J Clin Oncol.

Pharmacy Technician

The Thyroid Pharmacist

MARCH 7, 2025

to fluoride in my tap water, to hidden mold in my home, to my shampoo and deodorant (have you ever read those labels?!), 7] A recent report from 2024 found that fluoride exposure is associated with lower IQ in children, which has brought the issue of fluoridation front and center again (the U.S.

Health and Personal Care Stores

Pharmaceutical Technology

JULY 10, 2025

Ross Law July 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The global oncology market is set to grow at a compound annual growth rate (CAGR) of 24.5%. Image credit: CI Photos / Shutterstock. Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

Packaging

Express Pharma

JULY 4, 2025

The endometriosis market across the seven major markets (7MM*) is forecast to increase at a compound annual growth rate (CAGR) of 10.3 million in 2024 to $2.5 per cent from $938.0 billion in 2034, forecasts GlobalData. Beyond therapeutic innovation, increased awareness of endometriosis is contributing to the higher diagnosis rates.

Labelling

European Pharmaceutical Review

JANUARY 25, 2024

Therefore, extractables and leachables assessment should consider the packaging components of the CCS, including the labelling. Identification threshold: 10 ppm Qualification threshold: 20 ppm The FDA’s deadline for submitting comments on its draft guidance is 26 February 2024.

Documentation

ID Stewardship

OCTOBER 14, 2024

BCPS, BCIDP Article Posted October 2024, First Released in the October 2024 IDstewardship Newsletter 1. Read all about this in the product label here. More information on ganciclovir in the label here. Authored By: Timothy P. Gauthier, Pharm.D., Well, maybe not. Products can impact stability.

Labelling

The Thyroid Pharmacist

NOVEMBER 29, 2023

This is because I had learned about various adulterants found in supplements, how some supplement manufacturers don’t actually put the products that are on the label in the bottle, or that the dosages listed on the label may be completely different from what’s in the products. We have 95 expiring in March 2024.)

Health and Personal Care Stores

pharmaphorum

DECEMBER 16, 2022

The negotiations over the treaty are being hosted through the World Health Organization (WHO), with plans to officially adopt a binding agreement sealed by the United Nations health agency’s member countries in May 2024. The UN Special Rapporteur on contemporary forms of racism, E.

Vaccines

RX Note

JUNE 12, 2025

Such events may be related to professional practice and healthcare products, procedures and systems, including prescribing; order communication; product labelling, packaging and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use. 2017 Malaysia Patient Safety Goals 2.0,

Health and Personal Care Stores

Pharmaceutical Technology

JANUARY 10, 2023

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. Specifically, across all the major classes there are significant developments, label updates, and biosimilar launches that are driving their growth. billion in sales in 2019, increasing to $136.2

Biosimilars